Transgenic mouse expressing human FcRn protein

Details Transgenic mouse expressing human FcRn protein Transgenic mouse expressing human FcRn protein

2008-04-15

2008-04-15

Li, Q. Janice (Department: 1633)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S008000, C800S018000, C800S021000, C800S022000, C800S024000, C800S025000

Reexamination Certificate

active

07358416

ABSTRACT:
Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous RcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous RcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgene. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.

REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5877396 (1999-03-01), Ravetch et al.
patent: 6096871 (2000-08-01), Presta et al.
patent: 6121022 (2000-09-01), Presta et al.
patent: WO-2005/013912 (2005-02-01), None
Pearson, Nature 2002;415:8-9.
Linder, Lab Animal May 2001;30:34-9.
Nebert et al, Biochemical Pharmacol Feb. 1997;53:249-54.
Mullins et al, J Clin Invest Apr. 1996;97:1557-60.
Logan and Sharma, Clin Exp Pharmacol Physiol Dec. 1999;26:1020-25.
Lupus erythematosus. Wikipedia 2007.
Theofilopolos and Dixon,Adv. Immunol. 37:269-390 (1985).
Raghavan et al.,Immunity 1:303-315 (1994).
Morel et al.,Immunity 1:219-229 (1994).
Murphy and Roths,Arthritis Rheum. 22:1188-1194 (1979).
Andrews et al.,J. Exp. Med. 148:1198-1215 (1978).
Simister and Mostov,Nature 337:184-7 (1989).
Simister et al.,Eur. J. Immunol. 26:1527-31 (1996).
Ghetie et al.,Eur. J. Immunol. 26:690-696 (1996).
Ghetie and Ward,Annu. Rev. Immunol. 18:739-66 (2000).
Brambell et al.,Nature 203:1352-5 (1964).
Brambell, F.W.,Lancet. 2:1087-93 (1966).
Capecchi, M.R.,Trends Genet. 5:70-76 (1989).
Israel et al.,Immunology 89:573-578 (1996).
Karlsson et al.,Proc. Natl. Acad. Sci. USA 96:2244-2249 (1999).
Israel et al.,J. of Immun. 154:6246-6251 (1995).
Zhiya Yu et al., “Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases,” New England Journal of Medicine 340(3):227-228 (1999).
Amos Etzioni et al., “High Dose Intravenous Gammaglobulins in Autoimmune Disorders: Mode of Action and Therapeutic Uses,” Autoimmunity 3:307-315 (1989).
Robert A. Good et al., “Historic Aspects of Intravenous Immunoglobulin Therapy,” Cancer 68:1416-1419 (1991).
Akilesh et al., “The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease,”The Journal of Clinical Investigation, 113(9):1328-1333 (2004).
Chaudhury et al., “The major histocompatibility complex-related Fc receptor for lgG (FcRn) binds albumin and prolongs its lifespan,”Journal of Experimental Medicine, 197(3):315-322 (2003).
Getman et al., “Pharmacokinetic effects of 4C9, and anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment fo humoral autoimmune and alloimmune conditions,”Journal of Pharmaceutical Sciences, 94(4): 718-729 (2005).
Medesan et al., “Comparative Studies of Rat IGG to Further Delineate the FC: FCRN Interaction Site,”European Journal of Immunology, 28(7):2092-2100 (1998).
Ghetie et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nature Biotechnology 15:637-640 (1997).

Affiliated with

Also associated with

Rating

Transgenic mouse expressing human FcRn protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transgenic mouse expressing human FcRn protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mouse expressing human FcRn protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2779713